Cough and sputum production as risk factors for poor outcomes in patients with COPD
- PMID: 21353517
- DOI: 10.1016/j.rmed.2011.02.003
Cough and sputum production as risk factors for poor outcomes in patients with COPD
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in developed countries, and its prevalence is projected to increase over the coming decades. According to the World Health Organization, COPD will become the third leading cause of death worldwide by 2020. COPD has a chronic and progressive course, and is often aggravated by exacerbations, which typically arise as a result of bronchial infection. Exacerbations are characterised by periods of increasing acute symptoms, particularly cough, dyspnoea and production of sputum, which worsen airflow obstruction, further impair quality of life and generally require a change in regular medication. Exacerbations are the most common cause of medical visits, hospital admissions and death in patients with COPD, and frequent exacerbations worsen health status and may cause a permanent decline in lung function. Chronic cough and sputum production are common in the general population, but significantly more prevalent in patients with respiratory disorders; these symptoms have been suggested as a risk factor for exacerbations of COPD. This article will review the consequences of chronic cough and sputum production in patients with COPD and analyse whether these risk factors may be useful for identifying a specific phenotype of patient that requires different management to reduce the occurrence of exacerbations.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Exacerbations of chronic obstructive pulmonary disease.Respir Care. 2003 Dec;48(12):1204-13; discussion 1213-5. Respir Care. 2003. PMID: 14651761 Review.
-
Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis.Respir Med. 2010 Apr;104(4):534-41. doi: 10.1016/j.rmed.2009.10.026. Epub 2009 Nov 14. Respir Med. 2010. PMID: 19917525
-
[The importance of the at risk COPD patients (Stage 0) and clinical differences].Tuberk Toraks. 2008;56(4):382-9. Tuberk Toraks. 2008. PMID: 19123073 Turkish.
-
Development and validation of a cough and sputum assessment questionnaire.Respir Med. 2008 Nov;102(11):1545-55. doi: 10.1016/j.rmed.2008.06.009. Epub 2008 Jul 27. Respir Med. 2008. PMID: 18662868
-
[Impact of exacerbations on the clinical course of chronic obstructive pulmonary disease].Rev Clin Esp. 2011 Mar;211 Suppl 2:3-12. doi: 10.1016/S0014-2565(11)70006-6. Rev Clin Esp. 2011. PMID: 21596168 Review. Spanish.
Cited by
-
Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review.Molecules. 2022 Aug 28;27(17):5542. doi: 10.3390/molecules27175542. Molecules. 2022. PMID: 36080309 Free PMC article. Review.
-
Minimal Clinically Important Differences for Patient-Reported Outcome Measures of Cough and Sputum in Patients with COPD.Int J Chron Obstruct Pulmon Dis. 2020 Jan 29;15:201-212. doi: 10.2147/COPD.S219480. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 32099345 Free PMC article.
-
Pulmonary Dysfunction Augmenting Bacterial Aerosols in Leather Tanneries of Punjab, Pakistan.Int J Chron Obstruct Pulmon Dis. 2021 Oct 27;16:2925-2937. doi: 10.2147/COPD.S328129. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34737557 Free PMC article.
-
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.Respir Res. 2016 Sep 10;17(1):112. doi: 10.1186/s12931-016-0425-5. Respir Res. 2016. PMID: 27613392 Free PMC article. Review.
-
The Burden of Cough and Phlegm in People With COPD: A COPD Patient-Powered Research Network Study.Chronic Obstr Pulm Dis. 2020 Jan;7(1):49-59. doi: 10.15326/jcopdf.7.1.2019.0146. Chronic Obstr Pulm Dis. 2020. PMID: 31999902 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical